Fecal transplant to help liver cancer that worsened on first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been on atezolizumab and bevacizumab for at least 4 months and your cancer still got worse.
- You have at least one liver tumor that has not been treated yet and can be measured on a scan.
- You are up and around most of the day (ECOG 0 or 1).
- Your liver function is good (Child-Pugh A, meaning no or mild liver damage).
- Your blood counts and kidney/liver lab values are within safe limits.
- You do not have active or serious autoimmune disease, brain metastases, uncontrolled bleeding, or recent major surgery or infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the gut microbiome affects treatment response in patients with advanced liver cancer who are receiving immunotherapy. It involves a colonoscopy to collect samples and may help improve future treatments.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This trial tests whether a fecal microbiota transplant (FMT) can help overcome drug resistance in people with advanced liver cancer whose disease has worsened after a specific triple therapy (TACE, lenvatinib, and sintilimab). FMT involves transferring gut bacteria from a healthy donor to restore the balance of your gut microbiome, which may make your cancer more responsive to treatment again.
This trial tests a combination of fecal microbiota transplant (FMT), an immunotherapy drug (QL1706), a targeted therapy (bevacizumab), and chemotherapy (XELOX) as a first treatment for advanced colon cancer that has spread to the liver. The goal is to see if this mix can help shrink tumors and improve outcomes.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This trial tests a new combination treatment (PULSAR plus fecal microbiota transplant) for people with advanced liver cancer that stopped responding to initial therapy. It aims to see if this approach can help control the cancer again.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.